Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Trastuzumab with FLOT in HER2 Positive Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Phase 2Active, not recruiting
- Start
- May 2023
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA). Started May 2023; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT05715931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715931.